Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
HONG KONG - Hutchmed (China) Limited (NASDAQ/AIM: HCM; HKEX: 13), a commercial-stage biopharmaceutical company, announced today that its shareholders passed an ordinary resolution during an Extraordinary General Meeting (EGM). The resolution approved the sale and purchase of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited.
The transaction received overwhelming support from shareholders, with 475,229,253 votes in favor (99.9745%) and only 121,270 votes against (0.0255%). There were 1,670 withheld votes, which are not counted in the vote calculation.
All directors of Hutchmed, except for Ms. Ling YANG who was unable to attend due to prior overseas commitments, were present at the EGM. The meeting was facilitated by Computershare Investor Services (Jersey) Limited, which acted as the scrutineer for the poll.
Hutchmed focuses on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved globally, including in the US, Europe, and Japan.
The EGM, where the vote took place, was held on March 31, 2025, as indicated in the notice of EGM and the circular to shareholders, both dated March 14, 2025.
The total number of shares that entitled holders to attend and vote on the resolution at the EGM was 871,601,095. There were no shares entitling holders to attend and abstain from voting in favor, nor any shares for holders required under the Listing Rules to abstain from voting at the EGM.
This news is based on a press release statement from Hutchmed. The company continues to advance in its sector, with its first three medicines making significant inroads in the treatment of various diseases. The successful passing of the resolution marks a strategic move in Hutchmed’s ongoing business development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.